Artia Global Partners’s Alto Neuroscience ANRO Stock Holding History

Artia Global Partners’s Portfolio ANRO Stock Details ANRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-29,192	Closed	-$520K	–	63
2025 Q4	$520K	Buy	+29,192	New	+$368K	0.07%	52

Other funds holding ANRO

Alpha Wave Global New York $791M AUM 113.77% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Spruce Street Capital New York $416M AUM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Franklin Resources

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Millennium Management

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Artia Global Partners's ANRO Position: Q1 2026 in Review

Artia Global Partners sold out of Alto Neuroscience (ANRO) in Q1 2026, closing a stake of 29,192 shares — an estimated $520K sold.

Artia Global Partners first reported a position in ANRO in Q4 2025 and held it in 1 quarter. The position peaked at $520K in Q4 2025. 110 funds tracked by Wall St. Rank hold ANRO as of Q1 2026.

Artia Global Partners reported no remaining Alto Neuroscience position as of Q1 2026 after selling out during the quarter.
Artia Global Partners sold 29,192 Alto Neuroscience shares in Q1 2026, an estimated $520K.
Artia Global Partners first reported a position in Alto Neuroscience in Q4 2025 and held it in 1 quarter.
Artia Global Partners's Alto Neuroscience position peaked at $520K in Q4 2025.
110 funds tracked by Wall St. Rank held Alto Neuroscience as of Q1 2026.

Based on Artia Global Partners's 13F filing for Q1 2026, filed 15 May 2026.